The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis
Severe Periodontitis
About this trial
This is an interventional treatment trial for Severe Periodontitis
Eligibility Criteria
Inclusion Criteria: Patients must be systemically healthy, Class I dental category. Involved teeth must have periodontal disease detectible by periodontal examination. Subjects with deep vertical periodontal lesions (>6 mm) showing no radiographic crestal alveolar lamina dura Exclusion Criteria: Presence of any disease or medication that alters the immune system or interferes with healing ability Smokers (more than 10 cigarettes per day) External or internal tooth resorption Tooth perforation from the pulp cavity through the tip of the root exposing the tissue to material in the oral cavity. Pregnant or nursing mothers because hormonal factors may influence the condition. Allergies or adverse reactions to valacyclovir. Patients under the age of 18. Patients with renal impairment or reduced renal function. Patients requiring hemodialysis or peritoneal dialysis.
Sites / Locations
- University of California, San FranciscoRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
valacyclovir group
Control group
Patients (N=20) in the valacyclovir group will be received, at baseline, periodontal scaling + valacyclovir (500 mg, 3 times a day for 3 days) ("Valacyclovir" group).
Patients (N=20) in the control group will receive, at baseline, periodontal scaling + placebo medication, three times a day for 3 days ("Control" group).